Validation of cognitive complaints appears to improve mood in patients with persistent chemotherapy-cognitive impairment, Vanderbilt researchers report.

A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.

Women who are longtime smokers could potentially save their lives by undergoing lung screens on the same day they schedule mammograms, according to a study by Vanderbilt researchers published in the Journal of Medical Screening.

An indirect comparative effectiveness study using published data suggests that the targeted therapy olaparib should be re-evaluated for treating metastatic prostate cancer.

A significant reduction in annual well visits and immunizations during the COVID-19 pandemic has led to a vaccination gap among U.S. children and adolescents, especially with the human papillomavirus (HPV) vaccine for cancer prevention.

Vanderbilt-Ingram Cancer Center researchers will present data on clinical trials involving targeted therapies, immunotherapies and drug combination synergies at the 2021 American Society of Clinical Oncology Annual Meeting, June 4-8. The meeting is a virtual event this year.

A white blood cell, the TREM2/APOE/C1Q-positive macrophage, has been identified as a potential biomarker to predict recurrence of the most common type of kidney cancer and as a possible target for drug development.